Associations With Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa
- 15 August 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 54 (5), 489-495
- https://doi.org/10.1097/qai.0b013e3181d91788
Abstract
Objectives: Highly active antiretroviral therapy (HAART) has been available in government facilities in the Western Cape Province of South Africa since 2001. We aimed to investigate factors associated with virologic treatment failure in this setting. Design: Case-control study, matched on facility and on starting date and duration of HAART. Methods: Cases and controls were identified from clinic registers from May 2001 to June 2006. Cases were patients who switched to second-line therapy after confirmed virologic failure (2 consecutive viral loads above 1000 copies/mL). Controls were on first-line treatment with viral load <400 copies per milliliter at the time of case incidence. Results: One hundred thirty cases and 238 controls were selected from 8 clinics (median 16.6 months on HAART, interquartile range: 12.2-24.6). Treatment interruptions [adjusted odds ratio (AOR) 8.6, 95% confidence interval: 3.6 to 20.8], prior nevirapine-based prevention of mother-to-child transmission (PMTCT) treatment (AOR: 9.6, 95% confidence interval: 2.9 to 32.2), a baseline CD4 count less than 50 cells per microliter or from 50-150 cells per microliter (AOR: 6.6, 95% confidence interval: 2.3 to 18.8 and AOR: 5.8, 95% confidence interval: 2.1 to 16.3 compared with a baseline CD4 count of more than 150 cells/μL), and the use of nevirapine in the initial regimen (AOR: 2.5, 95% confidence interval: 1.4 to 4.7) were all independently associated with virologic treatment failure. Conclusions: In this setting, nevirapine in the initial HAART regimen or for PMTCT treatment is associated with virologic treatment failure, together with low CD4 count at ART initiation. Earlier initiation of HAART and access to improved triple therapy and PMTCT regimens are priorities for HIV programs in Southern Africa.Keywords
This publication has 25 references indexed in Scilit:
- Persistent Minority K103N Mutations among Women Exposed to Single‐Dose Nevirapine and Virologic Response to Nonnucleoside Reverse‐Transcriptase Inhibitor–Based TherapyClinical Infectious Diseases, 2009
- Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenAIDS, 2008
- Antiretroviral therapy and early mortality in South AfricaBulletin of the World Health Organization, 2008
- Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countriesBulletin of the World Health Organization, 2008
- Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese PatientsAIDS Research and Human Retroviruses, 2008
- Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?AIDS, 2008
- Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory SyndromeThe Journal of Infectious Diseases, 2007
- The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort StudyThe Journal of Infectious Diseases, 2005
- Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAIDS, 2004
- Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term StrategiesClinical Infectious Diseases, 2000